ES2422739T3 - Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB - Google Patents

Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB

Info

Publication number
ES2422739T3
ES2422739T3 ES08793529T ES08793529T ES2422739T3 ES 2422739 T3 ES2422739 T3 ES 2422739T3 ES 08793529 T ES08793529 T ES 08793529T ES 08793529 T ES08793529 T ES 08793529T ES 2422739 T3 ES2422739 T3 ES 2422739T3
Authority
ES
Spain
Prior art keywords
prevention
ucb
gro
msc
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08793529T
Other languages
English (en)
Inventor
Jong Wook Chang
Dal-Soo Kim
Yoon-Sun Yang
Won Il Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medipost Co Ltd
Original Assignee
Medipost Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipost Co Ltd filed Critical Medipost Co Ltd
Application granted granted Critical
Publication of ES2422739T3 publication Critical patent/ES2422739T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica para uso en la prevención de tumores cerebrales, en la que la composiciónfarmacéutica comprende citoblastos mesenquimatosos aislados de sangre del cordón umbilical y/o citoblastosmesenquimatosos propagados a partir de dichos citoblastos mesenquimatosos.
ES08793529T 2007-08-29 2008-08-27 Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB Active ES2422739T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20070087228 2007-08-29
US97296607P 2007-09-17 2007-09-17
KR1020080067247A KR101039235B1 (ko) 2007-08-29 2008-07-10 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
US8973308P 2008-08-18 2008-08-18
PCT/KR2008/005026 WO2009028870A2 (en) 2007-08-29 2008-08-27 Composition for the diagnosis, prevention or treatment of diseases related to cells expressing il-8 or gro-alpha, comprising ucb-mscs

Publications (1)

Publication Number Publication Date
ES2422739T3 true ES2422739T3 (es) 2013-09-13

Family

ID=40388015

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08793529T Active ES2422739T3 (es) 2007-08-29 2008-08-27 Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB

Country Status (10)

Country Link
US (2) US8506948B2 (es)
EP (1) EP2180896B1 (es)
JP (1) JP5529021B2 (es)
KR (1) KR101039235B1 (es)
CN (2) CN102776285A (es)
AU (1) AU2008293208A1 (es)
CA (1) CA2692232C (es)
ES (1) ES2422739T3 (es)
SG (1) SG184701A1 (es)
WO (1) WO2009028870A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101039235B1 (ko) 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
NZ591292A (en) 2008-08-20 2012-10-26 Anthrogenesis Corp Improved cell composition and methods of making the same
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012121577A2 (ko) * 2011-03-10 2012-09-13 이화여자대학교 산학협력단 Ｐｔｅｎ을 포함하는 줄기세포의 조직 재생능 강화용 조성물
DK2714059T3 (en) 2011-06-01 2019-01-21 Celularity Inc TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
US20130171115A1 (en) * 2011-12-30 2013-07-04 Gang Li Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
KR102053385B1 (ko) * 2012-02-01 2019-12-06 포항공과대학교 산학협력단 12량체 ｔｒａｉｌ 및 ｈｓｖ-ｔｋ 자살유전자를 동시에 발현하는 벡터 및 이를 이용한 항암 줄기세포 치료제
CN102731658B (zh) * 2012-05-15 2014-07-30 山东大学 一种Tat PTD-Endostatin重组蛋白及其制备方法与应用
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2890720B1 (en) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
GB201220573D0 (en) * 2012-11-15 2013-01-02 Univ Central Lancashire Methods of diagnosing proliferative disorders
CN103602625B (zh) * 2013-08-16 2015-09-30 苏州大学 含有重组腺病毒质粒的大肠杆菌及重组腺病毒的应用
WO2015089280A1 (en) * 2013-12-11 2015-06-18 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
JP6519727B2 (ja) * 2014-09-17 2019-05-29 国立大学法人山口大学 間葉系幹細胞の培養方法、および肝機能障害用治療剤の製造方法
SG11201707134WA (en) * 2015-03-06 2017-10-30 Ajou Univ Industry-Academic Coop Found Cell therapeutic agent for cancer treatment and combination therapy with same
CN104726411B (zh) * 2015-03-27 2017-06-23 中国人民解放军军事医学科学院基础医学研究所 抑制肿瘤生长的重组间充质干细胞及其制备方法与应用
EP3283529B1 (en) * 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
CA3045228C (en) * 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
CN108018287A (zh) * 2018-01-10 2018-05-11 扬州大学 一种抑制山羊卵泡颗粒细胞增殖的特异siRNA及方法
CN108553478B (zh) * 2018-04-02 2020-03-20 杭州师范大学 一种septin基因shRNA在制备septin基因活性抑制剂中的应用
US10835558B2 (en) * 2018-04-16 2020-11-17 Brahm Holdings, Inc. Mammalian birth tissue composition for tumor treatment
KR20220038485A (ko) * 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
KR102957585B1 (ko) * 2021-09-17 2026-04-28 가톨릭대학교 산학협력단 IAP(inhibitor of apoptosis) 단백질을 과발현하는 지방유래줄기세포의 배양액을 포함하는 간질환 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003207399A1 (en) 2002-02-19 2003-09-09 Medipost Co., Ltd. Isolation and culture-expansion methods of mesenchymal stem/progenitor cells from umbilical cord blood, and differentiation method of umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues
KR20040022134A (ko) * 2002-09-06 2004-03-11 송준석 인간 간엽줄기 세포와 p53 분비 아데노바이러스를 이용한항암치료방법
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
KR101130220B1 (ko) * 2003-06-27 2012-04-13 엔씨 메디컬 리서치 가부시키가이샤 간엽계 세포를 유효 성분으로 하는 뇌신경 질환 치료용 체내 투여용 약제
CN1984899B (zh) * 2004-05-12 2011-07-27 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂
NZ553695A (en) * 2004-08-16 2009-10-30 Cellres Corp Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
JP2006345726A (ja) * 2005-06-14 2006-12-28 Hamamatsu Univ School Of Medicine 脳腫瘍治療用発現ベクター
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
KR101022401B1 (ko) 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
KR101039235B1 (ko) 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물

Also Published As

Publication number Publication date
EP2180896A4 (en) 2011-10-26
JP2010537973A (ja) 2010-12-09
AU2008293208A1 (en) 2009-03-05
CA2692232C (en) 2016-11-22
SG184701A1 (en) 2012-10-30
WO2009028870A3 (en) 2009-04-23
KR101039235B1 (ko) 2011-06-07
CN101815522A (zh) 2010-08-25
KR20090023070A (ko) 2009-03-04
JP5529021B2 (ja) 2014-06-25
CA2692232A1 (en) 2009-03-05
US20100143261A1 (en) 2010-06-10
US8506948B2 (en) 2013-08-13
US20130189189A1 (en) 2013-07-25
CN102776285A (zh) 2012-11-14
WO2009028870A4 (en) 2009-06-04
EP2180896B1 (en) 2013-04-24
CN101815522B (zh) 2016-12-28
WO2009028870A2 (en) 2009-03-05
EP2180896A2 (en) 2010-05-05

Similar Documents

Publication Publication Date Title
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
WO2009026657A8 (en) Flavonoid ppar agonists
DOP2012000155A (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
AR078346A1 (es) Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
AR077333A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
EP4272757A3 (en) Modified nk-92 cells for treating cancer
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
EP3825419A3 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2011056688A3 (en) Molecular profiling for personalized medicine
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
NZ584606A (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
CL2008003282A1 (es) Poblacion de celulas humanas que expresan cd34 las cuales son obtenidas a partir de expansion de celulas de sangre de cordon umbilical en presencia de celulas menstruales humanas, metodo para obtener dichas celulas.